Dexcom (DXCM) Share-based Compensation (2010 - 2026)

Dexcom (DXCM) has 17 years of Share-based Compensation data on file, last reported at $43.3 million in Q1 2026.

• Quarterly Share-based Compensation rose 26.61% year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168.7 million (up 1.87% YoY) and the FY2025 annual result came in at $159.6 million, down 6.34% from the prior year.
• Share-based Compensation grew to $43.3 million in Q1 2026 per DXCM's latest filing, from $35.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $45.3 million in Q2 2025 and bottomed at $29.1 million in Q1 2022.
• The 5-year median for Share-based Compensation is $39.0 million (2023), against an average of $38.3 million.
• The widest annual swing landed in 2022, when Share-based Compensation gained 29.28%; it then fell 19.17% in 2025.
• Tracing DXCM's Share-based Compensation over 5 years: stood at $34.0 million in 2022, then climbed by 8.53% to $36.9 million in 2023, then advanced by 17.34% to $43.3 million in 2024, then retreated by 19.17% to $35.0 million in 2025, then rose by 23.71% to $43.3 million in 2026.
• Per Business Quant, the three latest DXCM Share-based Compensation figures stand at $43.3 million (Q1 2026), $35.0 million (Q4 2025), and $45.1 million (Q3 2025).

Peer Comparison